Search results for "modality"

showing 10 items of 651 documents

High frequency rotational ablation: an alternative in treating coronary artery stenoses and occlusions.

1993

OBJECTIVE--To prove the safety and effectiveness of high frequency rotational ablation of coronary artery stenoses and occlusion in humans. SUBJECTS--106 patients with symptoms (91 men, 15 women) who had 67 significant stenoses, mainly types B and C, and 46-chronic occlusions. MAIN OUTCOME MEASURES--Mean change in diameter stenosis after rotational angioplasty alone and in combination with percutaneous transluminal coronary angioplasty immediately after treatment and 24 hours and six months later; restenosis rates at six months; complication of treatment. RESULTS--Rotational ablation could not be used in five stenoses and 16 chronic occlusions because of inability to reach or cross the lesi…

AdultMaleReoperationmedicine.medical_specialtyPercutaneousmedicine.medical_treatmentLumen (anatomy)Catheter ablationCoronary DiseaseBalloonCoronary AngiographyRestenosisAngioplastyInternal medicinemedicineHumansAngioplasty Balloon Coronarybusiness.industryMiddle AgedAblationmedicine.diseaseCombined Modality TherapyCoronary VesselsStenosisTreatment OutcomeCardiologyCatheter AblationFemaleRadiologyCardiology and Cardiovascular MedicinebusinessResearch Article
researchProduct

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

2002

The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or autologous SCT and underwent a salvage NST. 18/22 patients (82%) engrafted after NST. 13/16 patients (81%) with active disease reached complete remission (CR). 11 of 13 patients developed GVHD. After first NST 10/11 patients (91%) engrafted. Six of seven patients with active disease reached CR. Three of five relapsing patients reached subsequent CR after donor lymphocyte infusions, termination of immun…

AdultMaleRiskMelphalanCancer Researchmedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentSalvage therapyGraft vs Leukemia EffectPilot ProjectsAcute lymphocytic leukemiamedicineHumansPhiladelphia ChromosomeSurvival rateSalvage TherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationImmunosuppressionHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryFludarabineSurvival RateTransplantationsurgical procedures operativeOncologyDisease ProgressionFeasibility StudiesFemalebusinessmedicine.drugLeukemia
researchProduct

Agenesis of the renal segment of inferior vena cava associated with venous stasis.

2010

Congenital anomalies of the inferior vena cava is an extremely rare vascular anomaly with controversial pathogenesis. Anomalies of the inferior vena cava (IVC) are present in 0.3% to 0.5% of otherwise healthy individual and in 0.6% to 2% of patients with other cardiovascular defects. The phenomenon of absence of the IVC has been described in a variety of ways such as absence, agenesis, anomalous, and interruption of a particular segment ([infra] hepatic, pre-renal, renal, or infrarenal) of the IVC. We describe a 42-year-old man with chronic venous insufficiency, without DVT, caused by congenital absence of renal segment of the IVC

AdultMaleSettore MED/09 - Medicina InternaCardiovascular AgentsVena Cava InferiorPhlebographySettore MED/11 - Malattie Dell'Apparato CardiovascolareCombined Modality TherapyExercise TherapyVenous InsufficiencyChronic DiseaseDiosminHumansAGENESIS OF THE RENAL SEGMENT OF INFERIOR VENA CAVA ASSOCIATED WITH VENOUS STASIS.Ultrasonography Doppler ColorTomography X-Ray ComputedStockings CompressionInternational angiology : a journal of the International Union of Angiology
researchProduct

Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients – Results of the COMPAS Study

2020

Abstract Introduction The Comparison of Methylphenidate and Psychotherapy in adult ADHD Study (COMPAS) was a prospective, randomized multicenter clinical trial, comparing methylphenidate (MPH) with placebo (PLAC) in combination with cognitive behavioral group psychotherapy (GPT) or individual clinical management (CM) over the period of 1 year. Here, we report results on treatment safety. Methods MPH and PLAC were flexibly dosed. Among 433 randomized patients, adverse events (AEs) were documented and analyzed on an “as received” basis during week 0–52. Electrocardiogram data were recorded at baseline and week 24. Results Comparing 205 patients who received ≥1 dose of MPH with 209 patients wh…

AdultMaleTachycardiamedicine.medical_specialtyAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentMedizin610 Medicine & healthPlaceboGroup psychotherapyYoung Adult2738 Psychiatry and Mental Health03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicinemedicinePalpitationsHumans2736 Pharmacology (medical)Pharmacology (medical)Prospective StudiesAdverse effectCognitive Behavioral TherapyHyperhidrosisMethylphenidatebusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapy3. Good health030227 psychiatryClinical trialPsychiatry and Mental healthAttention Deficit Disorder with Hyperactivity10054 Clinic for Psychiatry Psychotherapy and PsychosomaticsMethylphenidateCentral Nervous System StimulantsFemalePatient Safetymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugPharmacopsychiatry
researchProduct

Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura.

2003

Abstract Thrombotic thrombocytopenic purpura (TTP) is an uncommon hematologic thrombotic disorder characterized by fever, hemorrhagic and neurologic signs. The advent of plasma exchange has dramatically improved the prognosis of this disease, which was once inevitably fatal. However, mortality rates remain significant. Antiplatelet drugs have been widely used in combination with plasma exchange. In this pilot study we investigated the effects of an adjunctive therapy consisting of the continuous, intravenous infusion of dipyridamole, a modality of administration that has not been previously tested in this setting. Sixteen untreated TTP patients, diagnosed consecutively at our clinic, receiv…

AdultMaleTime FactorsCombination therapyThrombotic thrombocytopenic purpuraPilot ProjectsMethylprednisolonelaw.inventionRandomized controlled trialRefractorylawRecurrencemedicineHumansPlateletIn patientProspective StudiesInfusions IntravenousPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryPlatelet CountMortality rateRemission InductionHematologyDipyridamoleMiddle Agedmedicine.diseaseCombined Modality TherapyDipyridamoleTreatment OutcomeAnesthesiaFemalebusinessPlatelet Aggregation Inhibitorsmedicine.drugTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
researchProduct

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial

2014

Purpose To compare standard-of-care grid laser photocoagulation versus intravitreal ranibizumab (IVR) versus a combination of both in the treatment of chronic (>3 months) macular oedema secondary to branch retinal vein occlusion. Methods Prospective, randomized, multicentre clinical trial. Thirty patients with a best-corrected visual acuity (BCVA) between 20/320 and 20/40 were randomized 1:1:1 to receive grid laser or three monthly injections of 0.5 mg IVR or both followed by 3 months of observation. Results Mean change from baseline BCVA at month 6 was +2 letters [laser; 0.04 logMAR, 95% confidence interval (−0.17; 0.25)], +17 letters [IVR; 0.34 (0.19; 0.5)] and +6 letters [combination; 0.…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular Edemalaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialRecurrencelawRanibizumabOphthalmologyRetinal Vein OcclusionHumansMedicineProspective Studies030212 general & internal medicineMacular edemaAgedAged 80 and overLaser Coagulationbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence interval3. Good healthSurgeryClinical trialOphthalmologychemistryIntravitreal Injections030221 ophthalmology & optometryBranch retinal vein occlusionFemaleLasers SemiconductorRanibizumabmedicine.symptombusinessmedicine.drugActa Ophthalmologica
researchProduct

Timing flickers across sensory modalities

2009

In tasks requiring a comparison of the duration of a reference and a test visual cue, the spatial position of test cue is likely to be implicitly coded, providing a form of a congruency effect or introducing a response bias according to the environmental scale or its vectorial reference. The precise mechanism generating these perceptual shifts in subjective duration is not understood, although several studies suggest that spatial attentional factors may play a critical role. Here we use a duration comparison task within and across sensory modalities to examine if temporal performance is also modulated when people are exposed to spatial distractors involving different sensory modalities. Di…

AdultMaleVisual perceptionTime Factorsgenetic structuresAdolescentmedia_common.quotation_subjectExperimental and Cognitive PsychologyAcoustic Stimulation; Adolescent; Adult; Attention; Auditory Perception; Cues; Female; Humans; Male; Photic Stimulation; Psychophysics; Space Perception; Time Factors; Time Perception; Young Adult; Experimental and Cognitive Psychology; Sensory Systems; Artificial Intelligencebehavioral disciplines and activitiesTask (project management)Young AdultStimulus modalityArtificial IntelligencePerceptionPsychophysicsPsychophysicsHumansAttentionmedia_commonTiming flickers across sensory modalitiesResponse biasSensory SystemsOphthalmologyAcoustic StimulationDuration (music)Space PerceptionTime PerceptionAuditory stimuliAuditory PerceptionFemaleCuesPsychologypsychological phenomena and processesPhotic StimulationCognitive psychology
researchProduct

Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience

2007

This study reports the first evaluation of therapeutic response in Romanian patients with Gaucher disease type I, after therapy with Cerezyme recently became available in our country.24 patients (11-50 years) received Cerezyme 20-60 U/kg every two weeks for at least 18 months. Haemoglobin, platelet count, volume of the liver and spleen, plasma chitotriosidase and the severity score were assessed every 6 months; skeletal radiography and osteodensitometry were also monitored.Eleven patients were splenectomized before start of therapy. Eight patients had anaemia (mean haemoglobin 9.4 g/dl) and 14 patients, of whom 13 were without splenectomy, had thrombocytopenia (mean 65,692/mm3). Haemoglobin…

AdultMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPediatricsTime FactorsAdolescentBone diseasemedicine.medical_treatmentDiseaseWeight GainSeverity of Illness IndexHemoglobinsGeneticsmedicineHumansIn patientChildGenetics (clinical)ChemotherapyGaucher DiseasePlatelet CountRomaniabusiness.industryLiver DiseasesRomaniannutritional and metabolic diseasesAnemiaEnzyme replacement therapyMiddle Agedmedicine.diseaseCombined Modality TherapyThrombocytopeniaRecombinant Proteinslanguage.human_languageSurgeryHexosaminidasesTreatment OutcomeSplenomegalyQuality of LifeSplenectomylanguageGlucosylceramidaseFemaleBone DiseasesbusinessFollow-Up StudiesJournal of Inherited Metabolic Disease
researchProduct

The adjunctive use of a controlled-release chlorhexidine chip following treatment with a new ultrasonic device in supportive periodontal therapy: a p…

2007

Abstract:  Objective:  The aim of this randomised, split-mouth, controlled clinical trial was to evaluate the effectiveness of a controlled-release chlorhexidine chip (CHX chip) as an adjunctive therapy to scaling and root planing (SRP) with a newly developed ultrasonic device in supportive periodontal therapy (SPT). Materials and methods:  Twenty patients with moderate-to-severe chronic periodontitis, displaying at least four sites with probing depth (PD) ≥5 mm and persistent bleeding on probing (BOP), were recruited for the study. The target sites were randomly treated with either a newly developed piezo-driven ultrasonic device VectorTM- or ultrasonic system (VUS) + CHX chip or VUS alone…

AdultMalemedicine.drug_classUltrasonic TherapyBleeding on probingDental PlaqueDentistryUltrasonic deviceScaling and root planingAntisepticPeriodontal Attachment LossmedicineHumansDentistry (miscellaneous)Periodontal Diseasesbusiness.industryChlorhexidineChlorhexidineMiddle Agedmedicine.diseaseCombined Modality TherapyControlled releaseChronic periodontitisClinical trialDelayed-Action PreparationsAnti-Infective Agents LocalDental ScalingFemalemedicine.symptomEpidemiologic Methodsbusinessmedicine.drugInternational Journal of Dental Hygiene
researchProduct

[Arterial hypertension and prediabetes].

2016

Abstract Background and objectives The aim of this study was to assess the factors related to new diabetes in hypertensive. Patients and methods This prospective follow-up study involved 2588 non-diabetic, hypertensive patients. The total follow-up was 15,053 patient-years with a median of 3.4 years (interquartile interval 1.4–6.8). Results During the follow-up, 333 (13%) patients had new diabetes, with a conversion rate of 2.21 (95% confidence interval [CI], 1.98–2.46) 100/patients/year. In a Cox proportional hazard model including baseline characteristics and modifications during the follow-up the three components of metabolic syndrome (excluding blood pressure and glucose values) HR 1.69…

AdultMalemedicine.medical_specialty030204 cardiovascular system & hematologyPrediabetic State03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicinePrediabetesProspective StudiesFamily historyAgedProportional Hazards ModelsAged 80 and overbusiness.industryProportional hazards modelMiddle Agedmedicine.diseaseCombined Modality TherapyConfidence intervalPrimary PreventionEndocrinologyBlood pressureDiabetes Mellitus Type 2HypertensionFemaleMetabolic syndromebusinessFollow-Up StudiesMedicina clinica
researchProduct